Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Biliary Tract Neoplasms × Temozolomide × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7 Pancreatic Neoplasms 6 Ovarian Neoplasms 5 Neuroblastoma 4 Liver Neoplasms 4 Wilms Tumor 3 Somatostatinoma 3 Sarcoma 3 Rectal Neoplasms 3 Osteosarcoma 3 Neuroendocrine Tumors 3 Neuroectodermal Tumors, Primitive, Peripheral 3 Neoplasms 3 Medulloblastoma 3 Gastrointestinal Stromal Tumors 3 Astrocytoma 3 Zollinger-Ellison Syndrome 2 Vipoma 2 Testicular Neoplasms 2 Teratoma 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Prostatic Neoplasms 2 Pheochromocytoma 2 Ovarian Germ Cell Cancer 2 Optic Nerve Glioma 2 Oligodendroglioma 2 Neoplasm Metastasis 2 Kidney Neoplasms 2

Interventions

Gemcitabine 82 Cisplatin 65 Capecitabine 34 Oxaliplatin 31 durvalumab 29 pembrolizumab 24 Fluorouracil 23 Leucovorin 22 S 1 (combination) 16 lenvatinib 12 Nivolumab 12 Irinotecan 12 tremelimumab 10 Bevacizumab 10 130-nm albumin-bound paclitaxel 9 Injections 7 Immune Checkpoint Inhibitors 7 Docetaxel 7 apatinib 6 Trastuzumab 6 titanium silicide 5 surufatinib 5 irinotecan sucrosofate 5 camrelizumab 5 Folfox protocol 5 Drug Therapy 5 Carboplatin 5 Blood Specimen Collection 5 Albumin-Bound Paclitaxel 5 zanidatamab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04796454 2022-06-01

PAMICC

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡